| Literature DB >> 29478923 |
George E Gentsch1, Thomas Spruce2, Rita S Monteiro2, Nick D L Owens2, Stephen R Martin3, James C Smith4.
Abstract
Antisense morpholino oligomers (MOs) have been indispensable tools for developmental biologists to transiently knock down (KD) genes rather than to knock them out (KO). Here we report on the implications of genetic KO versus MO-mediated KD of the mesoderm-specifying Brachyury paralogs in the frog Xenopus tropicalis. While both KO and KD embryos fail to activate the same core gene regulatory network, resulting in virtually identical morphological defects, embryos injected with control or target MOs also show a systemic GC content-dependent immune response and many off-target splicing defects. Optimization of MO dosage and increasing incubation temperatures can mitigate, but not eliminate, these MO side effects, which are consistent with the high affinity measured between MO and off-target sequence in vitro. We conclude that while MOs can be useful to profile loss-of-function phenotypes at a molecular level, careful attention must be paid to their immunogenic and off-target side effects.Entities:
Keywords: Brachyury; GC content; TALEN; Xenopus; dosage; immune response; morpholino; null mutation; off-target; splicing
Mesh:
Substances:
Year: 2018 PMID: 29478923 PMCID: PMC5861998 DOI: 10.1016/j.devcel.2018.01.022
Source DB: PubMed Journal: Dev Cell ISSN: 1534-5807 Impact factor: 12.270
Figure 1TALEN-Induced Deletions Nullify Brachyury Function
(A) TALEN-induced 2- and 7-bp deletions in exon 1 of t (e1.2D) and exon 3 of t2 (e3.7D), and predicted frameshift translations generating truncated proteins of 59 and 170 amino acids (aa). These mutations were selected to generate a double heterozygous X. tropicalis line for the Brachyury paralogs t and t2 (tt2).
(B) t and t2 transcript levels in hetero- and homozygous embryos as measured by qRT-PCR at early neurula stage (n = 3, mean ± SD). Two-tailed t test: ∗p ≤ 0.05.
(C) Multi-probe WMISH for various mesoderm cell lineage and derivative markers (actc1; cardiac and skeletal muscle; cav1, notochord; hoxd8, pronephros; myh6, heart; tal1, ventral blood island; tbx6, paraxial mesoderm) in wild-type and Brachyury (t/t2) null (KO) embryos, as well as embryos injected with four MOs targeting t and t2 (t/t2 MO mix) at mid-tailbud stage. Scale bar, 0.5 mm.
Figure 7Optimizations of KD Conditions Can Reduce but Fail to Eliminate MO Side Effects
(A–C) Fold changes to transcript levels and alternative splicing under different doses of the t/t2 MO mix (4.5 or 18 ng) and incubation temperatures (22°C or 28.5°C) were quantified at late tailbud stage by qRT-PCR (n = 4, mean ± SD) or WMISH. Two-way ANOVA test: ∗p < 0.1; ∗∗∗p < 0.001. (A) Transcriptional mis-regulation (log2 scale) of the Brachyury target gene tbx6 and of MO side effect genes tp53, tp53inp1, and c3ar1. (B) Multi-probe WMISH for various mesoderm cell lineage and derivative markers (cav1, notochord; hoxd8, pronephros; myh6, heart; tal1, ventral blood island; tbx6, paraxial mesoderm) and single WMISH for the immune response-related gene c3ar1. White arrowheads point to the expression domains of tbx6 and cav1 that were not maintained in embryos without functional Brachyury. (C) Fold changes (log2 scale) to the alternative splicing (solid bar) and transcript level (filled bar) of the “off-target” genes dtymk, abi1, and bloc1s4.
(D) Measurements of the hybridization affinity (equilibrium dissociation constant Kd) between tsplice MO and target or off-target (including a point-mutant and a scrambled version) RNA oligonucleotides at 23°C and 35°C using biolayer interferometry (normalized instrument response versus MO concentration). The off-target sequence was derived from the most likely blocked site causing dtymk mis-splicing (see Figure 5E).
(E) Multi-probe WMISH for various mesoderm cell lineage and derivative markers and single WMISH for the immune response related genes tp53 and c3ar1 in various late tailbud embryos developed at 25°C–26°C. Injection of the t/t2 MO mix at 3 ng per embryo (3-fold above an inefficient dose of 1 ng) caused KO-like loss of tbx6 and cav1 expression domains, as indicated by white arrowheads, while keeping immune response at minimum.
(F) Dosage-dependent effects on mis-splicing and transcript fold changes (log2 scale) in cMO- and t/t2 MO-injected versus uninjected embryos quantified by qRT-PCR at early gastrula (st. 10+) and mid-tailbud (st. 26) stage (n = 3, mean ± SD).
One-way ANOVA test: ∗∗∗p < 0.001. Scale bars, 0.5 mm (B and E).
Figure 2Transcriptional Deviation from Genetic Counterpart Reveals Immune Response as MO Side Effect
(A) Principal component (PC) analysis of poly(A) RNA profiles at indicated tailbud stages resulting from biological triplicates of a t/t2 KD and KO experiment. The KD experiment involved uninjected (not labeled), control (cMO), and t/t2 MO-injected embryos. The KO experiment consisted of wild-type (WT) (not labeled), heterozygous (t−/+t2−/+; data points framed in black, not labeled) and homozygous (t/t2 KO) embryos.
(B) Jitter/boxplot and pie chart show pairwise transcriptional comparisons of cMO, t/t2 MO (KD), heterozygous (het), KO embryos with uninjected (uni), cMO, or wild-type (WT) embryos. Only fold changes with FDR ≤10% were colored: navy blue <25%, sky blue 25%–67%, orange 150%–400%, and red >400% compared with reference transcript level. Percentage number in pie chart represents percentage of genes that were unaffected (i.e., whose fold change are <1.5 or FDR >10% between indicated conditions).
(C) Venn diagram of genes with increased and decreased transcript levels (i.e., ≥1.5-fold change at FDR ≤10%). See Table S3 for corresponding gene list.
(D) Statistical significance (hypergeometric p value) of enrichment for some selected biological processes (BPs) among the indicated Venn fields.
(E) MO-triggered transcriptional signature of an immune response. Gray areas represent Newman-Girvan-based communities of enriched BPs associated with 842 genes in fields A, B, and C of the Venn diagram. See Table S4 for corresponding and other Venn field-specific gene set enrichment analyses.
Figure 3Ubiquitous Immune Response against MO Intensifies during Embryogenesis
(A) Panel of genes upregulated in control and t/t2 morphants associated with the immune response and genes downregulated in t/t2 morphants and null mutants representing the Brachyury-dependent core network. Heatmap to the right represents the binding map of Brachyury (t) in the proximity (±40 kb) of indicated transcription start sites (TSS) at early tailbud stage (Gentsch et al., 2013).
(B) WMISH of immune response related gene transcripts c3ar1, tp53inp1, and tp53 in uninjected (uni) embryos and embryos injected with 18 ng of cMO or t/t2 MO mix. Left bottom corner inset, dorsal view of tailbud head showing elevated transcript levels in the CNS. tp53 antisense probe did not discriminate active isoforms shown in D. Scale bar, 0.5 mm.
(C) Temporal dynamics of transcript fold changes (log2 scale) for a selected group of genes representing the Brachyury-directed core network (tbx6) and the immune response (c3ar1, tp53inp1, and tp53) in MO-injected versus uninjected embryos as measured by qRT-PCR (n = 3, mean ± SD). Two-tailed t test (≥1.5-fold change): ∗p ≤ 0.1; ∗∗p ≤ 0.01; and ∗∗∗p ≤ 0.001.
(D) Genome map of full length tp53 and Δ99tp53 transcript isoforms shows normalized transcript levels for uninjected (uni), control morphants (cMO), t/t2 morphants (t/t2 MO), wild-type (WT), t/t2 heterozygous (t/t2 het), and homozygous (t/t2 KO) mutant embryos at tailbud stages 26 and 34. Isoform-corresponding translation products with critical domains are on display below the heatmap: TAD, transactivation domain; DBD, DNA binding domain; NLS, nuclear localization signal; and OD, oligomerization domain.
Figure 4Intensity of Innate Immune Response Depends on GC Content of MO
(A) Assigning the induction of immune response-related genes tp53, tp53inp1, and c3ar1 to single splice- or translation-blocking MOs (MOsplice and MOtransl) of the t/t2 MO mix injected at 8 ng per embryo as well as to the cell lineage tracer sulforhodamine (coupled to dextran). The transcript fold change was determined at late tailbud stage by qRT-PCR (n = 4, mean ± SD). Two-tailed t test: ∗p ≤ 0.1.
(B and C) c3ar1 induction was increasing with the GC content of the injected MO as determined by qRT-PCR (n = 4, mean ± SD) and WMISH. Scale bar, 0.5 mm.
Figure 5MOs Can Cause Off-Target Mis-splicing
(A) Quantitative comparison of t transcript levels and splice junction usage between t/t2 MO-injected and uninjected tailbud embryos in a superimposed Sashimi plot. Canonical and cryptic splicing are shown with solid and dashed lines, respectively. Magnification of the first intron indicates position and altered usage (see arrow after abbreviation for various splice sites) of splice junctions caused by the t donor splice-blocking MO (MOsplice): a, acceptor splice site; d, canonical donor splice site; cr1-4, cryptic splice sites.
(B) Consensus sequence of all canonical donor splice junctions detected in the transcriptome of X. tropicalis tailbud embryos and best alignment with control and donor splice-blocking MOs.
(C) Seriated heatmap of differentially used intron clusters, transcript level changes, and MO match length at blocked splice junctions for indicated conditions compared with their uninjected controls. Selected intron clusters represent coupled splicing events that were inversely mis-regulated in either t/t2 MO- or cMO-injected tailbud embryos: inhibition of canonical (can) splicing caused alternative or cryptic (alt/cr) splice sites to be used more frequently. Blocked splice sites, 758 in t/t2 morphants and 153 control morphants, were observed with higher occurrences of reduced transcript levels (<67%; 165:54 and 19:1, respectively) and more consecutive MO base pairing (≥10; 92:26 and 49:2, respectively) than expected (nobs:nexp).
(D) Temporal dynamics of mis-splicing (solid bar) and transcript (filled bar) fold changes (log2 scale) for transcripts dtymk, abi1, bloc1s4, and t in control (cMO) and t/t2 morphants (t/t2 MO) from neurula (stage 15) to mid-tailbud (stage 26) to late tailbud stage (stage 34). Mis-splicing was quantified by qRT-PCR (n = 3, mean ± SD) using forward primers that span alternative or cryptic splice junctions (altSJ/crSJ) as shown above the bar graph for dtymk and t. Cryptic splice junction shortens first exon of t (colored blue). Changes in transcript levels were determined at indicated exons (e). See Key Resources Table for the design of qRT-PCR primers.
(E) Superimposed Sashimi plot of transcript dtymk whose splicing was affected by both cMO and t/t2 MO at tailbud stage. Canonical and alternative (between exons 2 and 5) splicing are shown with solid and dashed lines, respectively. The blocked donor splice site featured partial matches of ≥8 consecutive bases with the MOsplice of t and t2 as well as the cMO. The alignments show canonical Watson-Crick (vertical bar) and non-canonical wobble (colon) base pairing between the transcript and several MOs.
(F) Confirmation of the alignment-based predictions in E by injecting single MOs or tracer sulforhodamine as indicated. Fold changes (log2 scale) to the alternative splicing and transcript level of dtymk were quantified by qRT-PCR (n = 4, mean ± SD).
Two-tailed t test: ∗p < 0.1; ∗∗p < 0.01.
Figure 6Analysis of Public RNA-Seq Datasets Substantiates Identified MO Side Effects
Superscripts refer to the published datasets used in this study: 1Marlétaz et al., 2015; 2Dichmann et al., 2015; 3Noiret et al., 2016; 4Chung et al., 2014; and 5Campbell et al., 2016.
(A) Heatmap of MO-induced transcriptional mis-regulation (%, percentage compared with uninjected embryos) of c3ar1 (c3ar1.L), tp53inp1 (tp53inp1.L), and tp53 (tp53.L) in X. tropicalis and X. laevis (gene names in brackets) embryos at indicated developmental stages. Asterisks indicate statistical significance: ∗FDR ≤10%; ∗∗FDR ≤1%; and ∗∗∗FDR ≤0.1%. The (average) GC content and dosage of MO(s) are listed below the heatmap.
(B) Seriated heatmap of splice/transcript levels and MO match length at blocked splice junctions for MO-injected embryos compared with their uninjected controls. Selected intron clusters represent coupled splicing events that were inversely mis-regulated in embryos injected with cMO (153 intron clusters at tailbud stage) or the cdx1/2/4 MO mix (41 intron clusters at neurula stage): inhibition of canonical (can) splicing caused alternative or cryptic (alt/cr) splice sites to be used more frequently. Intron cluster-specific heatmap rows were sorted by the mis-regulation of canonical splicing in morphants.
(C) Superimposed Sashimi plot of transcript dtymk whose splicing was affected by cMO at early neurula stage (data from Marlétaz et al., 2015). Canonical and alternative (between exons 2 and 5) splicing are shown with solid and dashed lines, respectively. The blocked donor splice site of intron 3 contains 10 consecutive bases perfectly complementary to sequence of the cMO.
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|---|---|
| Mouse monoclonal anti-HA | Sigma | Cat#H9658; RRID: |
| Mouse monoclonal anti-c-Myc | Sigma | Cat#M5546; RRID: |
| Mouse monoclonal anti-α-tubulin | Sigma | Cat#T5168; RRID: |
| Anti-mouse IgG (H+L) horse radish peroxidase conjugate | Thermo Fisher Scientific | Cat#31430; RRID: |
| Fab fragments from polyclonal anti-digoxigenin conjugated to alkaline phosphatase | Roche | Cat#11093274910; RRID: |
| PhosphoSafe extraction buffer | Merck | Cat#71296 |
| complete EDTA-free protease inhibitors | Roche | Cat#11873580001 |
| TRIzol | Thermo Fisher Scientific | Cat#15596018 |
| digoxigenin-11-UTP | Roche | Cat#11277065910 |
| RiboLock RNase inhibitor | Thermo Fisher Scientific | Cat#EO0381 |
| 4-Nitro-blue tetrazolium chloride (NBT) | Roche | Cat#11383213001 |
| 5-Bromo-4-chloro-3'-indolyphosphate (BCIP) | Roche | Cat#11383221001 |
| digoxigenin-11-dUTP | Roche | Cat#11558706910 |
| mMessage mMachine T3 Transcription kit | Thermo Fisher Scientific | Cat#AM1348 |
| mMessage mMachine SP6 Transcription kit | Thermo Fisher Scientific | Cat#AM1340 |
| TruSeq RNA Library Prep Kit v2 | Illumina | Cat#RS-122-2001 |
| KAPA HiFi HotStart ReadyMix | Kapa Biosystems | Cat#KK2602 |
| TOPO TA cloning kit | Thermo Fisher Scientific | Cat#K4500 |
| Zero-Blunt TOPO cloning kit | Thermo Fisher Scientific | Cat#K2800 |
| Directional pENTR/TOPO cloning kit | Thermo Fisher Scientific | Cat#K2400 |
| Turbo DNase | Thermo Fisher Scientific | Cat#AM2238 |
| proteinase K | Thermo Fisher Scientific | Cat#AM2548 |
| SP6 RNA polymerase | Roche | Cat#11487671001 |
| T7 RNA polymerase | Roche | Cat#10881767001 |
| Terminal deoxynucleotidyl transferase | Thermo Fisher Scientific | Cat#EP0161 |
| RNase H minus and point-mutant M-MLV reverse transcriptase | Promega | Cat#M3681 |
| SYBR Green I master mix | Roche | Cat#04707516001 |
| Raw sequencing data (FASTQ) | This study | GEO: |
| This study | EXRC: | |
| This study | EXRC: | |
| Sulforhodamine-tagged morpholino, | GeneTools | |
| Sulforhodamine-tagged morpholino, | GeneTools | |
| Sulforhodamine-tagged morpholino, | GeneTools | |
| Sulforhodamine-tagged morpholino, | GeneTools | |
| Untagged morpholino, standard control MO: | GeneTools | N/A |
| Biotin-tagged | IDT | This study |
| Biotin-tagged | IDT | This study |
| Biotin-tagged | IDT | This study |
| Biotin-tagged scrambled | IDT | This study |
| Genotyping | Sigma | This study |
| Genotyping | Sigma | This study |
| Cloning | Sigma | This study |
| Cloning | Sigma | This study |
| Cloning | Sigma | This study |
| Cloning | Sigma | This study |
| Cloning | Sigma | This study |
| Cloning | Sigma | This study |
| Generating | Sigma | This study |
| Generating | Sigma | This study |
| Generating | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | |
| RT-qPCR for | Sigma | |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | |
| RT-qPCR for | Sigma | |
| RT-qPCR for | Sigma | This study |
| RT-qPCR for | Sigma | This study |
| Cellectis Bioresearch | N/A | |
| This study | N/A | |
| Golden Gate TALEN and TAL Effector Kit 2.0 | Addgene: goldengatev2 | |
| Source BioScience | IMAGE 5307982 | |
| RCIscript-GoldyTALEN plasmid | Addgene: 38142 | |
| N-terminal 3xHA pCS2+ destination vector | Nigel Messenger | Smith lab |
| C-terminal 3xHA pCS2+ destination vector | Nigel Messenger | Smith lab |
| myc-tagged | Kevin Dingwell | Smith lab |
| N/A | ||
| N/A | ||
| IMAGE: 7024946 | ||
| This study | N/A | |
| N/A | ||
| N/A | ||
| N/A | EXRC | |
| N/A | ||
| This study | N/A | |
| This study | N/A | |
| TAL Effector Nucleotide Targeter 2.0 | ||
| Bowtie2 v2.1.0 | ||
| Tophat v2.0.10 | ||
| STAR v2.5.2a | ||
| Samtools v1.3.1 | ||
| RSeQC v2.6.4 (Python) | ||
| IGV genome browser v2.3.92 | ||
| HOMER v4.8.3 | ||
| LeafCutter v1.0 (Python/R package) | ||
| splAdder v1.0 (Python) | ||
| Julia: Bio.Seq module | BioJulia Project | |
| HTSeq-count v0.5.4p3 (Python) | ||
| DESeq2 v1.14.1 (Bioconductor package) | ||
| limma v3.30.13 (Bioconductor package) | ||
| edgeR v3.16.5 (Bioconductor package) | ||
| GOstats v2.40.0 (Bioconductor package) | ||
| GSEABase v1.36.0 (Bioconductor package) | ||
| igraph v1.0.1 (R package) | ||
| seriation v1.2-1 (R package) | ||
| Matching v4.9-2 (R package) | ||
| R v3.3.1 | The R Foundation | |
| Bioconductor v3.5 | Bioconductor | |
| Perl v5.18.2 | The Perl Foundation | |
| Python v2.7.12 | Python Software Foundation | |
| Julia v0.5 | The Julia Community | |